Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
UCAR-T cells targeting B7-H3
- Development stage
- Unknown
- Lead developer
- The Second Affiliated Hospital of Soochow University
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous, Intrathecal, Intratumoral
01
Overview
UCAR-T cells targeting B7-H3 is an allogeneic (universal) chimeric antigen receptor (CAR) T-cell therapy designed to target B7-H3 (CD276), a transmembrane protein overexpressed in various solid tumors, including high-grade gliomas and glioblastoma. Unlike traditional autologous CAR-T therapies, UCAR-T cells are derived from healthy donors and engineered to prevent graft-versus-host disease (GvHD) and host-mediated rejection, typically by knocking out the T-cell receptor (TCR) and HLA molecules. This specific program is being evaluated by the Second Affiliated Hospital of Soochow University in a Phase 0/1 trial for patients with relapsed or refractory advanced glioma, aiming to provide an off-the-shelf therapeutic option for this aggressive malignancy.
- Other names
- B7-H3 UCAR-TB-7-H3 UCAR-TB 7-H3 UCAR-Tallogeneic B7-H3 CAR-T cellsB7-H3-targeted UCAR-T cellsB-7-H3-targeted UCAR-T cellsB 7-H3-targeted UCAR-T cells
02
Targets
B7-H3
Beyond the preview
Go deeper on UCAR-T cells targeting B7-H3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on UCAR-T cells targeting B7-H3.